BRANFORD, Conn. , Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc.
(NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business update. Q3 2024 and Recent Business Highlights: Completed a follow-on offering of $10 million in gross proceeds Dosed first Netherton syndrome patient with ATR-12 Submitted an IND to the FDA and received IND clearance for ATR-04 to treat skin rash from EGFR inhibitors Received Fast Track designation from the FDA for ATR-04 Presented positive preclinical data and the clinical plan of a Phase 1/2 clinical study of ATR-04 in a late-breaking presentation at the European Academy of Dermatology and Venereology (EADV) Congress Strengthened intellectual property (IP) portfolio with newly granted and allowed patents Francisco Salva , CEO of Azitra commented: "Azitra achieved a number of significant milestones in the third quarter of 2024 to propel our pipeline forward, highlighted by the dosing of the first patient with ATR-12 in our ongoing Netherton syndrome trial. Additionally during the quarter, we completed a follow-on offering of $10 million in gross proceeds, submitted an IND for ATR-04 for skin rash from epidermal growth factor receptor inhibitors (EGFRis), obtained IND clearance and Fast Track designation for ATR-04, and strengthened our IP portfolio.
"With a clear roadmap, strong .
